FLUDARABINE Side Effects

7015483-0 | Bacteraemia, Histiocytosis Haematophagic, Pyrexia
on Sep 20, 2010 Female patient from FRANCE , 84 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: bacteraemia, histiocytosis haematophagic, pyrexia. Fludarabine dosage: .

6999088-3 | Abdominal Pain, Acute Graft Versus Host Disease, Diffuse Large B-cell Lymphoma, Epstein-barr Virus Associated Lymphoproliferative Disorder, Melaena, Pyrexia
Patient was taking Fludarabine (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), acute graft versus host disease, diffuse large b-cell lymphoma, epstein-barr virus associated lymphoproliferative disorder, melaena, pyrexia on Sep 10, 2010 from UNITED STATES Additional patient health information: Male patient , 32 years of age, . Fludarabine dosage: Conditioning Regimen. During the same period patient was treated with CYCLOPHOSPHAMIDE (Conditioning Regimen) (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ).

6965089-4 | Dyspnoea, Hypotension, Hypoxia, Oxygen Saturation Decreased, Respiratory Rate Increased, Tachycardia
Adverse event was reported on Aug 09, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: 25 Mg/m2/kg) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED KINGDOM , 46 years of age, After Fludarabine was administered, patient had the following side effects: dyspnoea, hypotension, hypoxia, oxygen saturation decreased, respiratory rate increased, tachycardia. During the same period patient was treated with MFEZ (1.32 10e10 T-cells) (View Mfez Review and Mfez Label ), CYCLOPHOSPHAMIDE (60mg/m2/kg; Dose 5100mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), PROLEUKIN (7 Doses Of Iv Bolus Injection Of 24 Iu , Later 8 Iu) (View Proleukin Review and Proleukin Label ).

6944878-6 | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Cystitis Haemorrhagic, Cytomegalovirus Infection, Hydrocephalus, Meningitis Tuberculous, Pancytopenia, Pneumatosis Intestinalis, Pneumocystis Jiroveci Pneumonia
on Aug 18, 2010 Male patient from JORDAN , child 7 years of age, was diagnosed with stem cell transplant, t-cell depletion and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, cystitis haemorrhagic, cytomegalovirus infection (What is cytomegalovirus infection?), hydrocephalus (What is hydrocephalus?), meningitis tuberculous, pancytopenia, pneumatosis intestinalis, pneumocystis jiroveci pneumonia. Fludarabine dosage: Day -6 To -2. During the same period patient was treated with ALEMTUZUMAB (On Day Zero (second Stem Cell Transplantation)) (View Alemtuzumab Review and Alemtuzumab Label ), ANTI THYMOCYTE GLOBULIN NOS (Day - 6 To - 2) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), ANTI THYMOCYTE GLOBULIN NOS (Day - 6 To - 2) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYTARABINE (Day -6 To -3) (View Cytarabine Review and Cytarabine Label ), BUSULFAN (Day -8 To -7) (View Busulfan Review and Busulfan Label ), GRANULOCYTE COLONY STIMULATING FACTOR (On Day +5) (View Granulocyte Colony Stimulating Factor Review and Granulocyte Colony Stimulating Factor Label ). Patient was hospitalized.


6944690-8 | Dyspnoea, Hypotension, Hypoxia, Oxygen Saturation Decreased, Respiratory Rate Increased, Tachycardia
on Aug 09, 2010 Female patient from UNITED KINGDOM , 46 years of age, was diagnosed with colorectal cancer (What is colorectal cancer?) and was treated with Fludarabine (View Usage). Patient had the following side effects: dyspnoea, hypotension, hypoxia, oxygen saturation decreased, respiratory rate increased, tachycardia. Fludarabine dosage: 25 Mg/m2/kg. During the same period patient was treated with MFEZ (1.32 10e10 T-cells) (View Mfez Review and Mfez Label ), CYCLOPHOSPHAMIDE (60mg/m2/kg; Dose 5100mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), PROLEUKIN (7 Doses Of Iv Bolus Injection Of 24 Iu , Later 8 Iu) (View Proleukin Review and Proleukin Label ).

6944637-4 | Graft Versus Host Disease, Sepsis
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: graft versus host disease, sepsis (What is sepsis?) on Aug 13, 2010 from ITALY Additional patient health information: Male patient , 14 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and. Fludarabine dosage: . During the same period patient was treated with BUSULPHAN (View Busulphan Review and Busulphan Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6944634-9 | Bronchopulmonary Aspergillosis, Graft Versus Host Disease
Adverse event was reported on Aug 13, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and. Location: ITALY , child 10 years of age, Patient experienced the following unwanted or unexpected effects: bronchopulmonary aspergillosis, graft versus host disease. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ANTITYMOCYTE GLOBULIN (View Antitymocyte-globulin Review and Antitymocyte-globulin Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6938423-9 | Acute Myeloid Leukaemia Recurrent, Cytomegalovirus Test Positive, Encephalitis, Thrombotic Microangiopathy
on Aug 04, 2010 Male patient from JAPAN , 67 years of age, weighting 130.1 lb, was diagnosed with stem cell transplant, antifungal prophylaxis, infection prophylaxis and was treated with Fludarabine (View Usage). Patient had the following side effects: acute myeloid leukaemia recurrent, cytomegalovirus test positive, encephalitis (What is encephalitis?), thrombotic microangiopathy. Fludarabine dosage: . During the same period patient was treated with THYMOGLOBULIN (Total Daily Dose: 60 Mg) (View Thymoglobulin Review and Thymoglobulin Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), MICAFUNGIN SODIUM (View Micafungin Sodium Review and Micafungin Sodium Label ), CEFEPIME HYDROCHLORIDE (View Cefepime Hydrochloride Review and Cefepime Hydrochloride Label ), FILGRASTIM (GENETICAL RECOMBINATION) (View Filgrastim (genetical Recombination) Review and Filgrastim (genetical Recombination) Label ). Patient was hospitalized.

6938168-5 | Escherichia Test Positive, Urosepsis
on Aug 10, 2010 Male patient from GERMANY , 69 years of age, weighting 205.0 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: escherichia test positive, urosepsis. Fludarabine dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ACIC (View Acic Review and Acic Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), EMBOLEX (View Embolex Review and Embolex Label ). Patient was hospitalized.

6931491-X | Acute Myeloid Leukaemia, Cytomegalovirus Test Positive, Encephalitis, Thrombotic Microangiopathy
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, cytomegalovirus test positive, encephalitis (What is encephalitis?), thrombotic microangiopathy on Aug 04, 2010 from JAPAN Additional patient health information: Male patient , 67 years of age, weighting 130.1 lb, was diagnosed with infection prophylaxis and. Fludarabine dosage: . During the same period patient was treated with THYMOGLOBULIN (Total Daily Dose: 60 Mg) (View Thymoglobulin Review and Thymoglobulin Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), MICAFUNGIN SODIUM (View Micafungin Sodium Review and Micafungin Sodium Label ), CEFEPIME HYDROCHLORIDE (View Cefepime Hydrochloride Review and Cefepime Hydrochloride Label ), FILGRASTIM (GENETICAL RECOMBINATION) (View Filgrastim (genetical Recombination) Review and Filgrastim (genetical Recombination) Label ). Patient was hospitalized.

6927724-6 | Acute Graft Versus Host Disease, Burkitt's Lymphoma, Cholangitis Acute, Fungal Infection, Septic Shock
Adverse event was reported on Jul 27, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with burkitt's lymphoma and. Location: JAPAN , 59 years of age, Patient had the following side effects: acute graft versus host disease, burkitt's lymphoma, cholangitis acute, fungal infection (What is fungal infection?), septic shock. During the same period patient was treated with MELPHALAN (View Melphalan Review and Melphalan Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (High-dose, Two Courses) (View Methotrexate Review and Methotrexate Label ).

6921945-4 | Histiocytosis Haematophagic, Hodgkin's Disease
on Aug 09, 2010 Male patient from NETHERLANDS , 75 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: histiocytosis haematophagic, hodgkin's disease (What is hodgkin's disease?). Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6918583-6 | Acute Graft Versus Host Disease, Burkitt's Lymphoma, Cholangitis Acute, Fungal Infection, Septic Shock
on Jul 27, 2010 Male patient from JAPAN , 59 years of age, was diagnosed with burkitt's lymphoma and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, burkitt's lymphoma, cholangitis acute, fungal infection (What is fungal infection?), septic shock. Fludarabine dosage: . During the same period patient was treated with MELPHALAN (View Melphalan Review and Melphalan Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (High-dose, Two Courses) (View Methotrexate Review and Methotrexate Label ).

6916533-X | Cardiac Failure Acute, Multi-organ Failure, Septic Shock
Patient was taking Fludarabine (View Usage). Patient had the following side effects: cardiac failure acute, multi-organ failure, septic shock on Aug 03, 2010 from FRANCE Additional patient health information: Female patient , 56 years of age, was diagnosed with stem cell transplant, acute myeloid leukaemia, breast cancer female and. Fludarabine dosage: . During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), THYMOGLOBULIN (As Used: 5-10 Mg/m2) (View Thymoglobulin Review and Thymoglobulin Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), FLUOROURACIL (4 Or 6 Cycles) (View Fluorouracil Review and Fluorouracil Label ).

6915860-X | Myelodysplastic Syndrome, Pancytopenia, Squamous Cell Carcinoma Of The Cervix
Adverse event was reported on Jul 17, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: Day 1 - Day 3 (6 Cycles)) was diagnosed with chronic lymphocytic leukaemia, chronic lymphocytic leukaemia recurrent and. Location: GERMANY , 50 years of age, After Fludarabine was administered, patient had the following side effects: myelodysplastic syndrome, pancytopenia, squamous cell carcinoma of the cervix. During the same period patient was treated with CYCLOPHOSPHAMIDE (Day 1 - Day 3; Q Day 29 (6 Cycles)) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), VINCRISTINE (Day 1) (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

6905725-1 | Actinic Keratosis, Oesophageal Squamous Cell Carcinoma, Sweat Gland Tumour
on Jul 27, 2010 Male patient from UNITED KINGDOM , 32 years of age, was diagnosed with acute myeloid leukaemia, chronic graft versus host disease, stem cell transplant and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: actinic keratosis, oesophageal squamous cell carcinoma, sweat gland tumour. Fludarabine dosage: . During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MELPHALAN (View Melphalan Review and Melphalan Label ).

6905694-4 | Cardiac Failure Acute, Multi-organ Failure, Septic Shock
on Jul 22, 2010 Female patient from FRANCE , 56 years of age, was diagnosed with stem cell transplant, acute myeloid leukaemia, breast cancer female and was treated with Fludarabine (View Usage). Patient had the following side effects: cardiac failure acute, multi-organ failure, septic shock. Fludarabine dosage: . During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), THYMOGLOBULIN (As Used: 5-10 Mg/m2) (View Thymoglobulin Review and Thymoglobulin Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), FLUOROURACIL (4 Or 6 Cycles) (View Fluorouracil Review and Fluorouracil Label ).

6905613-0 | Acute Graft Versus Host Disease In Skin, Adenovirus Infection, Asthenia, Cough, Disturbance In Attention, Haemorrhage, Hepatic Failure, Multi-organ Failure, Pancytopenia
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: acute graft versus host disease in skin, adenovirus infection, asthenia, cough, disturbance in attention, haemorrhage, hepatic failure, multi-organ failure, pancytopenia on Jul 22, 2010 from FRANCE Additional patient health information: Male patient , 51 years of age, was diagnosed with stem cell transplant, chronic lymphocytic leukaemia transformation, graft versus host disease and. Fludarabine dosage: . During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), ALS (View Als Review and Als Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CORTICOSTEROIDS NOS (View Corticosteroids Nos Review and Corticosteroids Nos Label ).

6905612-9 | Acute Graft Versus Host Disease In Skin, Adenoviral Hepatitis, Asthenia, Cough, Cytolytic Hepatitis, Disseminated Intravascular Coagulation, Encephalopathy, Hepatic Failure, Hepatic Necrosis
Adverse event was reported on Jul 22, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with acute myeloid leukaemia, stem cell transplant, acute graft versus host disease in skin and. Location: FRANCE , 36 years of age, Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in skin, adenoviral hepatitis, asthenia, cough, cytolytic hepatitis, disseminated intravascular coagulation, encephalopathy, hepatic failure, hepatic necrosis. During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), ANTILYMPHOCYTE SERUM (View Antilymphocyte Serum Review and Antilymphocyte Serum Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ).

6882378-2 | Rash Erythematous, Rash Pruritic, Urticaria
on Jul 28, 2010 Male patient from UNITED STATES , 74 years of age, weighting 195.1 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). Patient had the following side effects: rash erythematous, rash pruritic, urticaria. Fludarabine dosage: 50 Mg Iv. Patient was hospitalized.

6827108-5 | Squamous Cell Carcinoma
on Jun 25, 2010 Male patient from NORWAY , 64 years of age, weighting 198.4 lb, was diagnosed with chronic lymphocytic leukaemia, antifungal prophylaxis and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: squamous cell carcinoma. Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ALEMTUZUMAB (View Alemtuzumab Review and Alemtuzumab Label ), TRIMETOPRIM SULPHAMETOXAZOL (80 Mg / 400 Mg) (View Trimetoprim - Sulphametoxazol Review and Trimetoprim - Sulphametoxazol Label ), VALACYCLOVIR (View Valacyclovir Review and Valacyclovir Label ).

6826186-7 | Cholestasis, Enterobacter Bacteraemia, Enterococcal Sepsis, Guillain-barre Syndrome, Hyperbilirubinaemia, Toxic Encephalopathy
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: cholestasis, enterobacter bacteraemia, enterococcal sepsis, guillain-barre syndrome (What is guillain-barre syndrome?), hyperbilirubinaemia, toxic encephalopathy on Jun 25, 2010 from BELGIUM Additional patient health information: Female patient , 49 years of age, was diagnosed with acute myeloid leukaemia and. Fludarabine dosage: Unk. During the same period patient was treated with CLOFARABINE (View Clofarabine Review and Clofarabine Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), OMEPRAZOLE (20 1x) (View Omeprazole Review and Omeprazole Label ), XANAX (0.5 3x Per Day) (View Xanax Review and Xanax Label ), ORGAMETRIL (View Orgametril Review and Orgametril Label ), NOXAFIL (Total Daily Dose: 15 Ml) (View Noxafil Review and Noxafil Label ), PURINETHOL (2 Per Day) (View Purinethol Review and Purinethol Label ).

6817620-7 | Actinic Keratosis, Oesophageal Squamous Cell Carcinoma, Sweat Gland Tumour
Adverse event was reported on May 18, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with acute myeloid leukaemia, chronic graft versus host disease, stem cell transplant and. Location: UNITED KINGDOM , 32 years of age, Patient had the following side effects: actinic keratosis, oesophageal squamous cell carcinoma, sweat gland tumour. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ).

6816268-8 | Actinic Keratosis, Oesophageal Squamous Cell Carcinoma, Sweat Gland Tumour
on May 18, 2010 Male patient from UNITED KINGDOM , 32 years of age, was diagnosed with acute myeloid leukaemia, chronic graft versus host disease, stem cell transplant and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: actinic keratosis, oesophageal squamous cell carcinoma, sweat gland tumour. Fludarabine dosage: . During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ).

6800666-2 | Acute Graft Versus Host Disease In Intestine, Cytomegalovirus Infection, Meningoencephalitis Herpetic
on Jun 12, 2010 Male patient from UNITED STATES , 55 years of age, was diagnosed with bone marrow conditioning regimen, prophylaxis against graft versus host disease, acute graft versus host disease in intestine and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine, cytomegalovirus infection (What is cytomegalovirus infection?), meningoencephalitis herpetic. Fludarabine dosage: . During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), ANTI THYMOCYTE GLOBULIN NOS (On Pre-transplant Days -4 And -3) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), IMMUNE GLOBULIN NOS (View Immune Globulin Nos Review and Immune Globulin Nos Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6800665-0 | Acute Graft Versus Host Disease In Skin, Cytomegalovirus Infection, Meningoencephalitis Herpetic
Patient was taking Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease in skin, cytomegalovirus infection (What is cytomegalovirus infection?), meningoencephalitis herpetic on Jun 12, 2010 from UNITED STATES Additional patient health information: Male patient , 41 years of age, was diagnosed with prophylaxis against graft versus host disease, antiviral prophylaxis, acute graft versus host disease in skin and. Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ANTI THYMOCYTE GLOBULIN NOS (On Pre-transplant Days -3, -2 And -1) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), IMMUNE GLOBULIN NOS (View Immune Globulin Nos Review and Immune Globulin Nos Label ), GANCICLOVIR (Monday Through Friday) (View Ganciclovir Review and Ganciclovir Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6794716-X | Acute Graft Versus Host Disease In Skin, Cytomegalovirus Infection, Meningoencephalitis Herpetic
Adverse event was reported on Jun 12, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with prophylaxis against graft versus host disease, antiviral prophylaxis, acute graft versus host disease in skin and. Location: UNITED STATES , 41 years of age, After Fludarabine was administered, patient had the following side effects: acute graft versus host disease in skin, cytomegalovirus infection (What is cytomegalovirus infection?), meningoencephalitis herpetic. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ANTI THYMOCYTE GLOBULIN NOS (On Pre-transplant Days -3, -2 And -1) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), IMMUNE GLOBULIN NOS (View Immune Globulin Nos Review and Immune Globulin Nos Label ), GANCICLOVIR (Monday Through Friday) (View Ganciclovir Review and Ganciclovir Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6794715-8 | Acute Graft Versus Host Disease In Intestine, Cytomegalovirus Infection, Meningoencephalitis Herpetic
on Jun 12, 2010 Male patient from UNITED STATES , 55 years of age, was diagnosed with bone marrow conditioning regimen, prophylaxis against graft versus host disease, acute graft versus host disease in intestine and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in intestine, cytomegalovirus infection (What is cytomegalovirus infection?), meningoencephalitis herpetic. Fludarabine dosage: . During the same period patient was treated with BUSULFEX (View Busulfex Review and Busulfex Label ), ANTI THYMOCYTE GLOBULIN NOS (On Pre-transplant Days -4 And -3) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), IMMUNE GLOBULIN NOS (View Immune Globulin Nos Review and Immune Globulin Nos Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6771158-4 | Acute Graft Versus Host Disease In Skin, Cholecystitis, Cytomegalovirus Infection, Febrile Neutropenia, Neurological Decompensation, Paraparesis
on Jun 02, 2010 Male patient from ITALY , 28 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease in skin, cholecystitis, cytomegalovirus infection (What is cytomegalovirus infection?), febrile neutropenia, neurological decompensation, paraparesis. Fludarabine dosage: On Days -6 To -2 Pre-transplant. During the same period patient was treated with TREOSULFAN (On Days -6 To -4 Pre-transplant) (View Treosulfan Review and Treosulfan Label ), RITUXIMAB (On Day -1 Transplant) (View Rituximab Review and Rituximab Label ), ATG FRESENIUS (On Days -4 To -2 Pre-transpalnt) (View Atg-fresenius Review and Atg-fresenius Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (Short Course) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6759829-7 | Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Herpes Zoster, Organising Pneumonia, Parainfluenzae Virus Infection, Septic Shock
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: acute graft versus host disease, chronic graft versus host disease, herpes zoster, organising pneumonia, parainfluenzae virus infection, septic shock on May 22, 2010 from UNITED STATES Additional patient health information: Female patient , 50 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease, acute graft versus host disease and. Fludarabine dosage: Five Doses. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (Two Doses) (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (X 6) (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6759822-4 | Acute Graft Versus Host Disease, Bronchopulmonary Aspergillosis, Cerebral Toxoplasmosis, Chronic Graft Versus Host Disease, Epstein-barr Virus Infection, Herpes Zoster, Organising Pneumonia, Pneumonia Bacterial, Respiratory Syncytial Virus Infection
Adverse event was reported on May 22, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: Three Doses) was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and. Location: UNITED STATES , 50 years of age, Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, bronchopulmonary aspergillosis, cerebral toxoplasmosis, chronic graft versus host disease, epstein-barr virus infection, herpes zoster, organising pneumonia, pneumonia bacterial, respiratory syncytial virus infection (What is respiratory syncytial virus infection?). During the same period patient was treated with BUSULFEX (Three Doses) (View Busulfex Review and Busulfex Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

6759820-0 | Acute Graft Versus Host Disease, Adenovirus Infection, Arthritis Bacterial, Bronchopulmonary Aspergillosis, Chronic Graft Versus Host Disease, Cytomegalovirus Infection, Enterococcal Bacteraemia, Influenza, Organising Pneumonia
on May 22, 2010 Female patient from UNITED STATES , 31 years of age, was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease, adenovirus infection, arthritis bacterial, bronchopulmonary aspergillosis, chronic graft versus host disease, cytomegalovirus infection (What is cytomegalovirus infection?), enterococcal bacteraemia, influenza, organising pneumonia. Fludarabine dosage: Five Doses. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (Two Doses) (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (On Days 1, 3, 6 And 11) (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ).

6759812-1 | Acute Graft Versus Host Disease, Cytomegalovirus Test Positive, Engraftment Syndrome, Pneumonia, Pulmonary Oedema, Pyrexia, Rash
on May 15, 2010 Male patient from KOREA, REPUBLIC OF , child 10 years of age, was diagnosed with bone marrow conditioning regimen, aplastic anaemia, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: acute graft versus host disease, cytomegalovirus test positive, engraftment syndrome, pneumonia (What is pneumonia?), pulmonary oedema, pyrexia, rash (What is rash?). Fludarabine dosage: Total Daily Dose: 30 Mg/m2. During the same period patient was treated with CYCLOPHOSPHAMIDE (Total Daily Dose: 60 Mg/kg) (View Cyclophosphamide Review and Cyclophosphamide Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ).

6759810-8 | Chronic Graft Versus Host Disease, Non-small Cell Lung Cancer Metastatic, Pneumocystis Jiroveci Pneumonia, Respiratory Failure, Respiratory Syncytial Virus Infection
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: chronic graft versus host disease, non-small cell lung cancer metastatic, pneumocystis jiroveci pneumonia, respiratory failure, respiratory syncytial virus infection (What is respiratory syncytial virus infection?) on May 22, 2010 from UNITED STATES Additional patient health information: Female patient , 44 years of age, was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and. Fludarabine dosage: Five Doses. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (On Days 1, 3, 6 And 11) (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ).

6759809-1 | Bacterial Sepsis, Candidiasis, Renal Tubular Necrosis, Serum Sickness
Adverse event was reported on May 22, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: Five Doses) was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and. Location: UNITED STATES , 63 years of age, Patient had the following side effects: bacterial sepsis, candidiasis, renal tubular necrosis, serum sickness. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (2 Doses) (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), MINI METHOTREXATE (On Days 1, 3, 6 And 11) (View Mini Methotrexate Review and Mini Methotrexate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ).

6755445-1 | Acute Graft Versus Host Disease, Adenovirus Infection, Arthritis Bacterial, Bronchopulmonary Aspergillosis, Chronic Graft Versus Host Disease, Cytomegalovirus Infection, Enterococcus Test Positive, Influenza, Organising Pneumonia
on May 22, 2010 Female patient from UNITED STATES , 31 years of age, was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: acute graft versus host disease, adenovirus infection, arthritis bacterial, bronchopulmonary aspergillosis, chronic graft versus host disease, cytomegalovirus infection (What is cytomegalovirus infection?), enterococcus test positive, influenza, organising pneumonia. Fludarabine dosage: Five Doses. During the same period patient was treated with MELPHALAN (Two Doses) (View Melphalan Review and Melphalan Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (On Days 1, 3, 6 And 11) (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ).

6755438-4 | Acute Graft Versus Host Disease, Bronchopulmonary Aspergillosis, Cerebral Toxoplasmosis, Chronic Graft Versus Host Disease, Epstein-barr Virus Infection, Herpes Zoster, Organising Pneumonia, Pneumonia Bacterial, Respiratory Syncytial Virus Infection
on May 22, 2010 Male patient from UNITED STATES , 50 years of age, was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, bronchopulmonary aspergillosis, cerebral toxoplasmosis, chronic graft versus host disease, epstein-barr virus infection, herpes zoster, organising pneumonia, pneumonia bacterial, respiratory syncytial virus infection (What is respiratory syncytial virus infection?). Fludarabine dosage: Three Doses. During the same period patient was treated with BUSULFEX (Three Doses) (View Busulfex Review and Busulfex Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

6755430-X | Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Herpes Zoster, Organising Pneumonia, Parainfluenzae Virus Infection, Septic Shock
Patient was taking Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease, chronic graft versus host disease, herpes zoster, organising pneumonia, parainfluenzae virus infection, septic shock on May 22, 2010 from UNITED STATES Additional patient health information: Female patient , 50 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease, acute graft versus host disease and. Fludarabine dosage: Five Doses. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (Two Doses) (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (X 6) (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6748628-8 | Bacterial Sepsis, Candidiasis, Renal Tubular Necrosis, Serum Sickness
Adverse event was reported on May 22, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: Five Doses) was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and. Location: UNITED STATES , 63 years of age, After Fludarabine was administered, patient had the following side effects: bacterial sepsis, candidiasis, renal tubular necrosis, serum sickness. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (2 Doses) (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), MINI METHOTREXATE (On Days 1, 3, 6 And 11) (View Mini Methotrexate Review and Mini Methotrexate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ).

6745404-7 | Acute Graft Versus Host Disease, Cytomegalovirus Test Positive, Engraftment Syndrome, Pneumonia, Pulmonary Oedema, Pyrexia, Rash
on May 15, 2010 Male patient from KOREA, REPUBLIC OF , child 10 years of age, was diagnosed with bone marrow conditioning regimen, aplastic anaemia, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, cytomegalovirus test positive, engraftment syndrome, pneumonia (What is pneumonia?), pulmonary oedema, pyrexia, rash (What is rash?). Fludarabine dosage: Total Daily Dose: 30 Mg/m2. During the same period patient was treated with CYCLOPHOSPHAMIDE (Total Daily Dose: 60 Mg/kg) (View Cyclophosphamide Review and Cyclophosphamide Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ).

6745403-5 | Chronic Graft Versus Host Disease, Non-small Cell Lung Cancer Metastatic, Pneumocystis Jiroveci Pneumonia, Respiratory Syncytial Virus Infection
on May 22, 2010 Female patient from UNITED STATES , 44 years of age, was diagnosed with stem cell transplant, mycosis fungoides, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient had the following side effects: chronic graft versus host disease, non-small cell lung cancer metastatic, pneumocystis jiroveci pneumonia, respiratory syncytial virus infection (What is respiratory syncytial virus infection?). Fludarabine dosage: Five Doses. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), TACROLIMUS (On Days 1, 3, 6 And 11) (View Tacrolimus Review and Tacrolimus Label ), MINI METHOTREXATE (On Days 1, 3, 6 And 11) (View Mini Methotrexate Review and Mini Methotrexate Label ), NEUPOGEN (From Day 7 Until Engraftment) (View Neupogen Review and Neupogen Label ).

6730760-6 | Acute Graft Versus Host Disease In Skin, Disseminated Intravascular Coagulation, Microangiopathy, Staphylococcal Sepsis
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: acute graft versus host disease in skin, disseminated intravascular coagulation, microangiopathy, staphylococcal sepsis on May 11, 2010 from JAPAN Additional patient health information: Female patient , 24 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and. Fludarabine dosage: . During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (Short-term Methotrexate) (View Methotrexate Review and Methotrexate Label ).

6703507-7 | Blood Bilirubin Increased, Candida Sepsis, Febrile Neutropenia, Pelvic Venous Thrombosis, Placental Insufficiency, Platelet Function Test Abnormal, Pneumonia Cytomegaloviral, Thrombocytopenia
Adverse event was reported on Feb 17, 2009 by a Female patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with acute myeloid leukaemia recurrent and. Location: UNITED STATES , 31 years of age, Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, candida sepsis, febrile neutropenia, pelvic venous thrombosis, placental insufficiency, platelet function test abnormal, pneumonia cytomegaloviral, thrombocytopenia. During the same period patient was treated with CYTARABINE (Total Daily Dose: 2000 Mg/m2) (View Cytarabine Review and Cytarabine Label ), MITOXANTRONE (On Treatment Days 2-3 Per Cycle (ham-protocol), Started In Week 22+2) (View Mitoxantrone Review and Mitoxantrone Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), GEMTUZUMAB OZOGAMICIN (View Gemtuzumab-ozogamicin Review and Gemtuzumab-ozogamicin Label ).

6703506-5 | Anaemia, Congenital Hydrocephalus, Foetal Growth Retardation, Peripartum Cardiomyopathy
on Feb 17, 2009 Male patient from UNITED STATES , weighting 3.74 lb, was diagnosed with acute myeloid leukaemia recurrent and was treated with Fludarabine (View Usage). Patient had the following side effects: anaemia, congenital hydrocephalus, foetal growth retardation, peripartum cardiomyopathy. Fludarabine dosage: . During the same period patient was treated with CYTARABINE (Maternal Ham-protocol Treatment Starting In Week 22+2) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), GEMTUZUMAB OZOGAMICIN (View Gemtuzumab-ozogamicin Review and Gemtuzumab-ozogamicin Label ), MITOXANTRONE (Maternal Ham-protocol Treatment Starting In Week 22+2) (View Mitoxantrone Review and Mitoxantrone Label ).

6698262-3 | B-cell Lymphoma, Dizziness, Nausea
on Apr 13, 2010 Male patient from SWEDEN , 60 years of age, weighting 191.8 lb, was diagnosed with chronic lymphocytic leukaemia, prophylaxis, pulmonary embolism (What is pulmonary embolism?) and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: b-cell lymphoma, dizziness (What is dizziness?), nausea (What is nausea?). Fludarabine dosage: Cycle 4. During the same period patient was treated with ALEMTUZUMAB (Total Daily Dose: 30 Mg) (View Alemtuzumab Review and Alemtuzumab Label ), CYCLOPHOSPHAMIDE (Cycle 4) (View Cyclophosphamide Review and Cyclophosphamide Label ), VALACICLOVIR (View Valaciclovir Review and Valaciclovir Label ), SULPHAMETHOXAZOLE (View Sulphamethoxazole Review and Sulphamethoxazole Label ), DALTEPARIN (View Dalteparin Review and Dalteparin Label ). Patient was hospitalized.

6698253-2 | Amyloidosis, Blood Pressure Decreased, Cardiovascular Disorder, Cytomegalovirus Viraemia, Diarrhoea, Renal Impairment
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: amyloidosis, blood pressure decreased, cardiovascular disorder, cytomegalovirus viraemia, diarrhoea, renal impairment on Apr 13, 2010 from JAPAN Additional patient health information: Female patient , 61 years of age, was diagnosed with diffuse large b-cell lymphoma and. Fludarabine dosage: 3 Courses. During the same period patient was treated with RITUXIMAB (3 Courses) (View Rituximab Review and Rituximab Label ).

6696175-4 | Hypotension, Lymphopenia, Multi-organ Failure, Normochromic Normocytic Anaemia, Pain In Extremity, Paraesthesia, Pneumonia, Pyrexia, Renal Impairment
Adverse event was reported on Apr 16, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: Six Cycles Fc) was diagnosed with non-hodgkin's lymphoma, antifungal prophylaxis and. Location: SWITZERLAND , 56 years of age, Patient had the following side effects: hypotension, lymphopenia, multi-organ failure, normochromic normocytic anaemia, pain in extremity, paraesthesia, pneumonia (What is pneumonia?), pyrexia, renal impairment. During the same period patient was treated with CYCLOPHOSPHAMIDE (Six Cycles Fc) (View Cyclophosphamide Review and Cyclophosphamide Label ), COTRIM (View Cotrim Review and Cotrim Label ). Patient was hospitalized.

6696035-9 | Chronic Lymphocytic Leukaemia Transformation, Escherichia Bacteraemia, Infection, Oral Candidiasis, Oral Herpes, Pyrexia
on Apr 07, 2010 Male patient from TURKEY , 56 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: chronic lymphocytic leukaemia transformation, escherichia bacteraemia, infection (What is infection?), oral candidiasis, oral herpes, pyrexia. Fludarabine dosage: 2 Cycles Fludarabine And Cyclophosphamide. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CYCLOPHOSPHAMIDE (2 Cycles Of Cyclophosphamide And Fludarabine) (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (Cyclophosphamide-vincristine-prednisolone) (View Vincristine Review and Vincristine Label ), MITOXANTRONE (Fludarabine-mitoxantrone-dexamethasone) (View Mitoxantrone Review and Mitoxantrone Label ), DEXAMETHASONE (Fludarabine-mitoxantrone-dexamethasone) (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6696034-7 | Blood Creatinine Increased, Chronic Graft Versus Host Disease, Convulsion, Device Related Sepsis, Haemoglobin Decreased, Platelet Count Decreased, Red Blood Cell Schistocytes Present, Thrombotic Microangiopathy
on Apr 09, 2010 Male patient from AUSTRALIA , 50 years of age, was diagnosed with stem cell transplant and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, chronic graft versus host disease, convulsion, device related sepsis, haemoglobin decreased, platelet count decreased, red blood cell schistocytes present, thrombotic microangiopathy. Fludarabine dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

6696033-5 | Acute Graft Versus Host Disease, Blood Creatinine Increased, Confusional State, Haemoglobin Decreased, Platelet Count Decreased, Red Blood Cell Schistocytes Present, Sepsis, Thrombotic Microangiopathy
Patient was taking Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease, blood creatinine increased, confusional state, haemoglobin decreased, platelet count decreased, red blood cell schistocytes present, sepsis (What is sepsis?), thrombotic microangiopathy on Apr 09, 2010 from AUSTRALIA Additional patient health information: Female patient , 20 years of age, was diagnosed with stem cell transplant and. Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).